EPS for Sophiris Bio, Inc. (SPHS) Expected At $-0.10

March 18, 2018 - By Kurt Siggers

 EPS for Sophiris Bio, Inc. (SPHS) Expected At $ 0.10
Investors sentiment decreased to 0.64 in 2017 Q3. Its down 1.96, from 2.6 in 2017Q2. It dived, as 6 investors sold Sophiris Bio, Inc. shares while 5 reduced holdings. 3 funds opened positions while 4 raised stakes. 1.63 million shares or 1.31% less from 1.65 million shares in 2017Q2 were reported.
Savings Bank Of Montreal Can accumulated 210 shares. Blackrock accumulated 75,895 shares. Vanguard Grp accumulated 776,205 shares. 333,641 are held by Sabby Mngmt Ltd Com. Royal Retail Bank Of Canada reported 6,811 shares. Bankshares Of Ny Mellon Corporation reported 17,500 shares. Wells Fargo Mn reported 0% in Sophiris Bio, Inc. (NASDAQ:SPHS). Jpmorgan Chase Com reported 22,011 shares. Guggenheim Cap Limited Liability Com, a Illinois-based fund reported 10,975 shares. Financial Bank Of America Corporation De owns 3,338 shares or 0% of their US portfolio. Virtu Ltd Liability Company has invested 0% in Sophiris Bio, Inc. (NASDAQ:SPHS). The Illinois-based Citadel Limited Liability Corp has invested 0% in Sophiris Bio, Inc. (NASDAQ:SPHS). Geode Mgmt Lc has 19,042 shares for 0% of their portfolio. Morgan Stanley invested in 5,000 shares. B T Dba Alpha has 0.01% invested in Sophiris Bio, Inc. (NASDAQ:SPHS) for 10,128 shares.

Analysts expect Sophiris Bio, Inc. (NASDAQ:SPHS) to report $-0.10 EPS on March, 26.They anticipate $0.03 EPS change or 42.86 % from last quarter’s $-0.07 EPS. After having $-0.11 EPS previously, Sophiris Bio, Inc.’s analysts see -9.09 % EPS growth. The stock increased 4.31% or $0.09 during the last trading session, reaching $2.18. About 195,963 shares traded. Sophiris Bio, Inc. (NASDAQ:SPHS) has risen 192.94% since March 18, 2017 and is uptrending. It has outperformed by 176.24% the S&P500.

Sophiris Bio, Inc. (NASDAQ:SPHS) Ratings Coverage

Among 6 analysts covering Sophiris Bio (NASDAQ:SPHS), 6 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Sophiris Bio had 11 analyst reports since August 30, 2016 according to SRatingsIntel. The firm earned “Buy” rating on Friday, June 9 by H.C. Wainwright. The company was maintained on Thursday, June 8 by Maxim Group. Maxim Group maintained it with “Buy” rating and $600 target in Monday, August 14 report. The firm earned “Buy” rating on Thursday, September 15 by Roth Capital. As per Wednesday, January 17, the company rating was maintained by H.C. Wainwright. The firm earned “Buy” rating on Friday, August 11 by H.C. Wainwright. The company was maintained on Friday, November 10 by H.C. Wainwright. The stock of Sophiris Bio, Inc. (NASDAQ:SPHS) earned “Overweight” rating by Piper Jaffray on Tuesday, August 30. TH Capital initiated it with “Buy” rating and $8 target in Thursday, September 15 report. The firm earned “Buy” rating on Friday, September 15 by H.C. Wainwright.

Sophiris Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development of products for the treatment of urological diseases. The company has market cap of $65.64 million. The company's primary product candidate is PRX302, which is in Phase III clinical trial for treatment of lower urinary tract symptoms of benign prostatic hyperplasia , as well as for the treatment of localized low to intermediate risk prostate cancer. It currently has negative earnings. It has a strategic relationship with Kissei Pharmaceutical Co., Ltd. for the development and commercialization of PRX302 and other products for the treatment of the symptoms of BPH, prostate cancer, prostatitis, or other diseases of the prostate; and license agreement with UVIC Industry Partnerships Inc. and The Johns Hopkins University with respect to the use of PRX302 for the development of therapeutics for the symptoms of BPH, prostate cancer, and other non-cancer diseases and conditions of the prostate.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.